Unite for ALS

Who We Are

Unite Platform Sign Up

Research Webinar: Targeting the Brain for ALS Therapies

New Study Investigating Long-term Safety, Effectiveness of Reldesemtiv

SBT-272, in Phase 1 Trial, Continues to Protect Motor Neurons in Mice

New research on the experimental drug, NU-9

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved RADICAVA ORS®

#ACTforALS Funding Opportunity Annoucement

Locanabio's Proprietary CORRECTx™ RNA-Targeting Gene Therapy Reduces Disease-Causing Hexanucleotide Repeat Expansions

ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)

Mutations in 22 Genes Linked to Sporadic ALS in Large Group Study

Scott's Story

Potential window for treating ALS Identified

Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035

ProJenX launches to advance novel, targeted therapies for ALS

Brainstorm Cell Therapeutics Inc NurOwn has taken the ALS community by storm with new genetic data

Motor neuron toxin associated with ALS identified

EverythingALS joins together with MTHA to research new digital biomarkers for #ALS.

Tau Protein Levels May Be Useful Biomarkers of ALS Progression

Amarna Therapeutics and Redoxis receive EUREKA Eurostars grant to establish a screening platform for the advancement of a potential first-in-class gene therapy for ALS

NurOwn Dosing Likely to Continue for ALS Patients in Its EAP

YOUR ALS GUIDE: For ALS Caregivers

ALS PATHWAYS: ALS CAREGIVERS SUPPORT

I AM ALS: CAREGIVING TOOLKIT